In one paragraphArticle in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Randi ChenKuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.ORCID https://orcid.org/0000-0003-3747-7964 Timothy A DonlonKuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.ORCID https://orcid.org/0000-0001-6545-6533 Vanessa L CunananKuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.ORCID https://orcid.org/0009-0009-0306-7175 Kaon FongKuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.
Keisuke MiyamotoDepartment of Internal Medicine, University of Hawaii, Honolulu, HI, USA.
Bradley J Willcox *Kuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.ORCID https://orcid.org/0000-0001-9890-3520 Kamal H Masaki *Kuakini Japan-Hawaii Cancer Study, Kuakini Honolulu Heart Program, Center of Biomedical Research Excellence (COBRE) for Clinical and Translational Research on Aging, Department of Research, Kuakini Medical Center, Honolulu, HI, USA.ORCID https://orcid.org/0000-0003-1170-3118 Funding
Epidemiology of Brain Aging in the Very OldU01AG019349 · NIA · KUAKINI MEDICAL CENTER · PI WHITE, LON RAY · 2001 to 2011
$14.0MProductive and Leisure Activities and Cognition in Later LifeP20GM125526 · NIGMS · KUAKINI MEDICAL CENTER · PI LEE, YEONJUNG · 2019 to 2023
$12.0MFOXO3 Genotype, InflammAging, Cardiovascular Disease, and Dementia. Kuakini Hawaii Lifespan Study III. Administrative Supplement.R01AG027060 · NIA · KUAKINI MEDICAL CENTER · PI Gregory J. Tranah, BRADLEY JOHN WILLCOX · 2005 to 2026
$8.1MEnergy-sensing Pathways, Healthy Aging and LongevityR01AG038707 · NIA · KUAKINI MEDICAL CENTER · PI WILLCOX, BRADLEY JOHN · 2011 to 2014
$1.4MHONOLULU HEART PROGRAMN01HC005102 · HC · KUAKINI MEDICAL CENTER · PI CURB, JESS DAVID · 1990 to 1997
–NHLBI NIH HHS N01 HC005102NIA NIH HHS R01 AG027060NIA NIH HHS R01 AG038707NIA NIH HHS U01 AG019349NIGMS NIH HHS P20 GM125526
6 · The paper itselfAbstract
Background: Smoking cessation lowers lung cancer (LC) risk, but the magnitude of risk reduction varies across individuals. FOXO3, a key regulator of cellular stress-response and longevity pathways, may influence susceptibility to LC after smoking cessation. The aim of the present study was to investigate whether Methods: We examined 4,339 ever-smoking American men of Japanese ancestry who were free of LC at baseline in the Kuakini Japan-Hawaii Cancer Study (1971-1975; mean age, 60 years). Participants were genotyped for Results: During 28 years of follow-up, 180 LC cases occurred, including 117 non-small cell lung cancer (NSCLC) cases. Significant interactions were observed between smoking status and Conclusions:
Indexed as
FOXO3 genotypegene-environment interactionlung cancer (LC)non-small cell lung cancer (NSCLC)Smoking cessation
Identifiers
PMID42582819
PMCPMC13458757
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390